Toward a More Nuanced Science Journalism
By Gina Maranto, Biopolitical Times guest contributor
| 05. 29. 2011
Last week, Chicago Tribune reporter Monica Eng wrote about the latest chapter in the debate over genetically modified foods: their unavoidable creep into spaces and places assumed to be GM-free. Eng's counterintuitive lede describes anti-GMO protestors improbably marching outside a Whole Foods – a sign of just how bad the situation has gotten, when even purveyors of organics can't guarantee untainted fare.
The online version features several sobering visuals: a graph showing the disquieting rise in GM soy and corn production over the last decade (such plants now represent 93% and 86% of the US harvest, respectively); a map highlighting states currently deliberating policies to label GM foods; a table listing some of the 40 countries that currently require such labeling. Eng summarizes the industry and environmental health arguments, provides the obligatory pro and con quotations, refers to a couple key surveys of public attitudes about GMOs, mentions some recent epidemiological work, and ends with a boilerplate statement from Monsanto proclaiming the utter adequacy of the status quo ante to ensure "food safety" as supported by "satisfied" experts in...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...